Simultaneous versus staged resection for synchronous colorectal liver metastases: The win ratio approach

Am J Surg. 2023 Mar;225(3):461-465. doi: 10.1016/j.amjsurg.2022.11.015. Epub 2022 Nov 19.

Abstract

Introduction: In order to investigate the optimal approach for synchronous colorectal liver metastases (sCRLM), we sought to use the "win ratio" (WR), a novel statistical approach, to assess the relative benefit of simultaneous versus staged surgical treatment.

Methods: Patients who underwent hepatectomy for sCRLM between 2008 and 2020 were identified from a multi-institutional database. The WR approach was utilized to compare composite outcomes of patients undergoing simultaneous versus staged resection.

Results: Among 1116 patients, 642 (57.5%) presented with sCRLM; 290 (45.2%) underwent simultaneous resection, while 352 (54.8%) underwent staged resection. In assessing the composite outcome, staged resection yielded a WR of 1.59 (95%CI 1.47-1.71) over the simultaneous approach for sCRLM. The highest WR occurred among patients requiring major hepatectomy (WR = 1.93, 95%CI 1.77-2.10) compared with patients who required minor liver resection (WR = 1.55, 95%CI 1.44-1.70).

Conclusions: Staged resection was superior to simultaneous resection for sCRLM based on a WR assessment.

Keywords: Multi-institutional study; Simultaneous resection; Staged resection; Synchronous colorectal liver metastases; Win ratio.

MeSH terms

  • Colorectal Neoplasms* / pathology
  • Colorectal Neoplasms* / surgery
  • Databases, Factual
  • Hepatectomy / adverse effects
  • Humans
  • Liver Neoplasms* / secondary
  • Retrospective Studies
  • Treatment Outcome